Temozolomide vs. Temozolomide and Thalidomide Treatment in Recurrent Glioblastoma
Status:
Unknown status
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the efficacy and safety of intensive dose temozolomide
treatment alone in parallel to a combination with thalidomide in patients with recurrent
glioblastoma after standard therapy.
In the treatment arm A of the study it will be investigated whether or not continuous dosing
of temozolomide may overcome alkylator resistance in patients with glioblastoma who progress
on the 5/28 day dosing regimen.
For treatment arm B it is postulated that the combination of thalidomide and temozolomide is
effective with respect to time to progression and progression-free survival due to the fact
that temozolomide and thalidomide have different mechanisms of action.